Sunshine Biopharma Inc (SBFM)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $2.22M
Last updated: Nov 17, 2026 at 11:05 AM ET
Sunshine Biopharma Inc (SBFM) Earnings: Report Dates and Results
Sunshine Biopharma (SBFM) is expected to report earnings on Apr 1, 2027. In the quarter ended Sep 30, 2026, Sunshine Biopharma reported EPS of -$5.20, below the -$3.40 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SBFM has an expected report date of Apr 1, 2027.
Earnings History
Of the 12 quarters below that had an estimate, SBFM beat 4 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $9.44M, up 0.2% from $9.42M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$5.20 | -$3.40 | -$3.40 - -$3.40 | -52.94% | Miss | N/A | 1 | 1 up, 0 down | Nov 12, 2026 | $9.44M |
| Jun 30, 2026 | -$1.15 | -$1.20 | -$1.20 - -$1.20 | +4.17% | Beat | N/A | 1 | 0 up, 1 down | Aug 13, 2026 | $9.26M |
| Mar 31, 2026 | -$2.50 | -$1.60 | -$1.60 - -$1.60 | -56.25% | Miss | N/A | 1 | 0 up, 0 down | Apr 3, 2026 | $8.09M |
| Dec 31, 2025 | -$0.46 | -$0.12 | N/A | -283.33% | Miss | N/A | 1 | 0 up, 1 down | Feb 25, 2026 | $8.58M |
| Sep 30, 2025 | -$1.90 | -$1.30 | -$1.30 - -$1.30 | -46.15% | Miss | N/A | 1 | 0 up, 1 down | Nov 13, 2025 | $9.42M |
| Jun 30, 2025 | -$3.90 | -$1.10 | N/A | -254.55% | Miss | N/A | N/A | 0 up, 0 down | Aug 12, 2025 | $9.41M |
| Mar 31, 2025 | -$0.44 | $0.07 | N/A | -728.57% | Miss | N/A | N/A | 0 up, 0 down | May 15, 2025 | $8.90M |
| Sep 30, 2024 | -$9.40 | -$5,350.00 | N/A | +99.82% | Beat | N/A | N/A | 0 up, 0 down | Nov 5, 2024 | $8.44M |
| Jun 30, 2024 | -$1,988.00 | -$6.00 | N/A | N/A | N/A | N/A | 1 | 0 up, 0 down | Aug 18, 2024 | $9.30M |
| Mar 31, 2024 | -$400.00 | -$208.00 | N/A | -92.31% | Miss | N/A | 1 | 1 up, 0 down | May 20, 2024 | $7.54M |
| Dec 31, 2023 | -$5.00 | -$3.00 | -$3.00 - -$3.00 | -66.67% | Miss | N/A | 1 | 0 up, 0 down | Mar 28, 2024 | $7.68M |
| Sep 30, 2023 | -$800.00 | -$1,200.00 | -$1,200.00 - -$1,200.00 | +33.33% | Beat | N/A | 1 | 0 up, 0 down | Nov 13, 2023 | $5.96M |
| Jun 30, 2023 | -$400.00 | -$1,600.00 | N/A | +75.00% | Beat | N/A | N/A | N/A | Aug 10, 2023 | $5.56M |
| Mar 31, 2023 | -$1.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 4, 2023 | $4.89M |
| Dec 31, 2022 | -$416,411.90 | N/A | N/A | N/A | N/A | -160158524.2% | N/A | N/A | Dec 31, 2022 | $3.94M |
| Sep 30, 2022 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 7, 2022 | $132808 |
| Jun 30, 2022 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 3, 2022 | $150307 |
| Mar 31, 2022 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 6, 2022 | $122645 |
| Dec 31, 2021 | $0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 21, 2022 | $85118 |
| Sep 30, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2021 | $50376 |
| Jun 30, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 9, 2021 | $52874 |
| Mar 31, 2021 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2021 | $40058 |
| Dec 31, 2020 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2021 | $28013 |
| Sep 30, 2020 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2020 | $17150 |
| Jun 30, 2020 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 19, 2020 | $15145 |
| Mar 31, 2020 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 30, 2020 | $11102 |
| Dec 31, 2019 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | $10556 |
| Sep 30, 2019 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2019 | $7326 |
| Jun 30, 2019 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 15, 2019 | $3033 |
| Mar 31, 2019 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 12, 2019 | $206 |
| Dec 31, 2018 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2019 | N/A |
| Sep 30, 2018 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 16, 2018 | N/A |
| Jun 30, 2018 | -$0.37 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 17, 2018 | N/A |
| Mar 31, 2018 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 2, 2018 | $91168 |
| Dec 31, 2017 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2018 | N/A |
| Sep 30, 2017 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 15, 2017 | N/A |
| Jun 30, 2017 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2017 | N/A |
| Mar 31, 2017 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 17, 2017 | N/A |
| Dec 31, 2016 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2017 | N/A |
| Sep 30, 2016 | -$1.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$6.70, after -$2,397.40 the year before. It was -$3.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$6.70 | N/A |
| Dec 31, 2024 | -$2,397.40 | N/A |
| Dec 31, 2023 | -$1,206.05 | N/A |
| Dec 31, 2022 | -$416,412.24 | -181048901.3% |
| Dec 31, 2021 | $0.23 | N/A |
| Dec 31, 2020 | -$0.04 | N/A |
| Dec 31, 2019 | -$0.08 | N/A |
| Dec 31, 2018 | -$0.74 | N/A |
| Dec 31, 2017 | -$0.50 | N/A |
| Dec 31, 2016 | -$3.10 | N/A |
Frequently Asked Questions About SBFM
When is Sunshine Biopharma's next earnings date?
Sunshine Biopharma's next earnings report is expected for Apr 1, 2027.
Did SBFM beat earnings estimates last quarter?
No. Sunshine Biopharma reported EPS of -$5.20 for the quarter ended Sep 30, 2026, below the -$3.40 estimate by 52.94%.
What EPS do analysts expect from SBFM next quarter?
The consensus EPS estimate for Sunshine Biopharma for the quarter ending Dec 31, 2026 is -$5.92 from 3 analysts.
How often does SBFM beat earnings estimates?
Sunshine Biopharma beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -164.73%.
SBFM pages: Overview, Earnings, Forecast, Financials, Competitors